• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    11/14/24 5:13:57 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    SC 13G/A 1 d854179dsc13ga.htm SC 13G/A SC 13G/A

     

     

    United States

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    CareDX, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    14167L103

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 14167L103

     

     1.   

     Names of Reporting Persons

     

     Bellevue Asset Management (UK) Ltd.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     England and Wales

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     3,128,913

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     3,128,913

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,128,913

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11.  

     Percent of Class Represented by amount in Row (9)

     

     5.8%

    12.  

     Type of Reporting Person (See Instructions)

     

     FI


    CUSIP No. 14167L103

     

     1.   

     Names of Reporting Persons

     

     Bellevue Group AG

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Switzerland

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     3,145,546

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     3,145,546

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     3,145,546

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11.  

     Percent of Class Represented by amount in Row (9)

     

     5.9%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO, HC


    CUSIP No. 14167L103

     

     1.   

     Names of Reporting Persons

     

     Bellevue Asset Management AG

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☒  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Switzerland

    Number of

    Shares  Beneficially 

    Owned by

    Each

    Reporting

    Person

    with:

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     16,543

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     16,543

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     16,543

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

     ☐

    11.  

     Percent of Class Represented by amount in Row (9)

     

     0.0%

    12.  

     Type of Reporting Person (See Instructions)

     

     CO, HC, FI


    Item 1

    1(a) Name of Issuer: CareDX, Inc.

    1(b) Address of Issuer’s Principal Executive Offices:

    3260 Bayshore Boulevard, Brisbane, CA 94005

    Item 2

    2(a) Name of Person Filing: Bellevue Group AG (“Bellevue Group”) on behalf of its wholly-owned subsidiaries, Bellevue Asset Management (UK) Ltd. (“BAM UK”) and Bellevue Asset Management AG (“BAM,” and together with Bellevue Group and BAM UK, the “Reporting Persons”).

    2(b) Address of Principal Business Office or, if none, Residence:

    Bellevue Group: Seestrasse 16, Kuesnacht, Switzerland, CH-8700

    BAM:     Seestrasse 16, Kuesnacht, Switzerland, CH-8700

    BAM UK:  32 London Bridge Street, 24th Floor, London, England SE1 9SG

    2(c) Citizenship:

    Bellevue Group: Switzerland

    BAM: Switzerland

    BAM UK: England and Wales

    2(d) Title of Class of Securities: Common Stock

    2(e) CUSIP Number: 14167L103

    Item 4. Ownership

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    This statement is filed jointly by Bellevue Group, BAM and BAM UK. BAM UK is a wholly-owned subsidiary of BAM. Each of BAM UK and BAM is a wholly-owned subsidiary of Bellevue Group.


    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    By signing below I also certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to investment advisers and investment companies is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.


    SIGNATURES

    After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Bellevue Asset Management (UK) Ltd.      
    Date: November 14, 2024     By:  

    /s/ Markus Peter

          Signatory Authority
        Name:   Markus Peter
        Title:   Director
    Bellevue Group AG      
    Date: November 14, 2024     By:  

    /s/ Stefano Montalbano

          Signatory Authority
        Name:   Stefano Montalbano
        Title:   Chief Financial Officer
    Date: November 14, 2024     By:  

    /s/ Christoph Eisenring

          Signatory Authority
        Name:   Christoph Eisenring
        Title:   Head Legal & Compliance
    Bellevue Asset Management AG      
    Date: November 14, 2024     By:  

    /s/ Martin Gubler

          Signatory Authority
        Name:   Martin Gubler
        Title:   Chief Financial Officer
    Date: November 14, 2024     By:  

    /s/ Ivo Betschart

          Signatory Authority
        Name:   Ivo Betschart
        Title:   Chief Finance & Controlling
    Get the next $CDNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CareDx upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

      1/15/25 7:29:19 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • Wells Fargo initiated coverage on CareDx with a new price target

      Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

      8/28/24 7:38:28 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx upgraded by BTIG Research with a new price target

      BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00

      8/19/24 8:49:21 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Financials

    Live finance-specific insights

    See more
    • CareDx to Report First Quarter 2025 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

      4/8/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to

      2/11/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Preliminary Financial Results for Third Quarter 2024

      Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi

      10/15/24 6:00:00 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CDNA
    Leadership Updates

    Live Leadership Updates

    See more

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CDNA
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/14/24 5:13:57 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/8/24 2:34:10 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/5/24 6:07:26 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • Director Cournoyer Christine sold $235,929 worth of shares (16,700 units at $14.13), decreasing direct ownership by 31% to 37,045 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/8/25 4:31:15 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Secretary and General Counsel Novack Jeffrey Adam sold $39,514 worth of shares (2,688 units at $14.70), decreasing direct ownership by 2% to 121,350 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/7/25 4:38:39 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,873 shares, decreasing direct ownership by 2% to 124,038 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/5/25 4:53:42 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints Jing Huang Chief Data and AI Officer

      CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac

      10/9/24 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

      CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e

      9/12/24 7:01:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan

      4/16/24 4:02:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports First Quarter 2025 Results

      First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted EBITDA of $4.6 million,

      4/30/25 4:05:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ ("CareDx" or the "Company")— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. Foley's employment with CareDx. CareDx granted Ms. Foley 36,231 restricted stock units ("RSUs") pursuant to the Company's 2016 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Company's Board o

      4/21/25 4:01:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx to Report First Quarter 2025 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

      4/8/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      5/6/25 5:00:40 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by CareDx Inc.

      10-Q - CareDx, Inc. (0001217234) (Filer)

      4/30/25 4:18:38 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CareDx, Inc. (0001217234) (Filer)

      4/30/25 4:11:42 PM ET
      $CDNA
      Medical Specialities
      Health Care